Lipella Pharmaceuticals I... (LIPO)
2.55
-0.17 (-6.25%)
At close: Mar 28, 2025, 3:59 PM
2.56
0.51%
After-hours: Mar 28, 2025, 06:30 PM EDT
Company Description
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus.
The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Dec 19, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Dr. Jonathan Kaufman M.B.A., Ph.D. |
Contact Details
Address: 7800 Susquehanna St. Pittsburgh, Pennsylvania United States | |
| Website | https://www.lipella.com |
Stock Details
| Ticker Symbol | LIPO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001347242 |
| CUSIP Number | 53630L100 |
| ISIN Number | US53630L1008 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan Kaufman M.B.A., Ph.D. | Co-Founder, Chairman, Chief Executive Officer, President, Secretary & Treasurer |
| Douglas Johnston CPA | Chief Financial Officer |
| Dr. Michael B. Chancellor M.D. | Co-Founder, Chief Medical Officer & Director |
| Katie Johnston | Controller |
| Michele Gruber | Director of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 17, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 17, 2025 | 4 | Filing |
| Mar 11, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 11, 2025 | 4 | Filing |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 03, 2025 | 4 | Filing |
| Mar 03, 2025 | 8-K | Current Report |